Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
When it comes to cutting‑edge cancer care, understanding the treatment details is essential for patients traveling from abroad. Liv Hospital’s internationally accredited team offers a transparent roadmap for immunotherapy, guiding patients through every phase—from initial assessment to long‑term follow‑up. According to recent global oncology reports, immunotherapy now accounts for over 20% of newly approved cancer therapies, underscoring its growing importance.
In this page, we break down the specific treatment details of immunotherapy programs available at Liv Hospital, focusing on how they are personalized, administered, and monitored. Whether you are seeking information for a newly diagnosed patient or planning a second opinion, the content below provides a clear, step‑by‑step guide designed for international patients who expect comprehensive support throughout their journey.
Our aim is to empower you with knowledge, reduce uncertainty, and illustrate how Liv Hospital integrates advanced science with compassionate care to deliver optimal outcomes.
Immunotherapy harnesses the body’s own immune system to identify and destroy cancer cells. Unlike traditional chemotherapy, which attacks rapidly dividing cells indiscriminately, immunotherapy targets specific pathways, offering a more precise attack on malignant tissue.
The treatment details of immunotherapy involve several key components:
At Liv Hospital, a multidisciplinary tumor board reviews each case to determine the most suitable immunotherapy approach. The board includes oncologists, radiologists, pathologists, and supportive care specialists, ensuring that every decision reflects the latest scientific evidence and the patient’s personal preferences.
These modalities illustrate the breadth of options that shape the overall treatment details for each patient.
Personalization lies at the heart of immunotherapy planning. Liv Hospital employs a systematic process to define the precise treatment details for every individual.
The resulting plan outlines the exact dosage, frequency, and duration of therapy, forming the core of the treatment details that will be communicated to the patient and their family.
This template demonstrates how the hospital translates clinical data into clear, actionable treatment details for the patient.
Liv Hospital follows internationally recognized protocols, adapting them to each patient’s unique profile. Below are the most frequently used regimens, along with their specific treatment details such as dosing, administration, and expected timelines.
Each protocol’s treatment details are documented in a patient‑specific treatment manual, which includes preparation steps, infusion times, and emergency procedures.
These comparisons help patients and caregivers quickly grasp the core treatment details that differentiate each option.
Immunotherapy can trigger immune‑related adverse events (irAEs) that differ from chemotherapy side effects. Understanding the expected treatment details for monitoring and managing these reactions is crucial for safety and comfort.
Liv Hospital provides a dedicated oncology nursing team that educates patients on early warning signs and supplies a 24/7 hotline for urgent concerns.
These treatment details empower patients to act quickly, minimizing complications and maintaining treatment continuity.
International patients often face logistical challenges in addition to medical considerations. Liv Hospital’s 360‑degree support service ensures that every element of the patient’s experience aligns with the detailed treatment plan.
The following checklist outlines the essential steps patients should complete before their first immunotherapy session, reflecting the comprehensive treatment details that Liv Hospital provides.
By following these steps, patients ensure that the logistical treatment details are in place, allowing them to focus on the therapeutic aspects of their care.
Continuous evaluation is a cornerstone of effective immunotherapy. Liv Hospital employs a structured follow‑up schedule that aligns with the individualized treatment details outlined at the start of therapy.
If imaging or clinical markers indicate insufficient response, the oncology team may modify the regimen—adding a second checkpoint inhibitor, switching to a different agent, or enrolling the patient in a clinical trial. All modifications are documented in an updated treatment plan, preserving clarity for the patient and their support network.
This systematic approach ensures that the evolving treatment details remain aligned with the patient’s clinical status and personal goals.
Liv Hospital combines JCI accreditation, state‑of‑the‑art facilities, and a dedicated international patient program to deliver world‑class cancer immunotherapy. Our multidisciplinary teams speak multiple languages, coordinate travel logistics, and provide personalized care plans that respect cultural preferences. With a proven track record in advanced oncology, Liv Hospital offers the expertise and supportive environment that international patients need for successful treatment outcomes.
Ready to discuss your personalized immunotherapy plan? Contact Liv Hospital’s International Patient Services today to schedule a free virtual consultation and start your journey toward effective cancer care.
Send us all your questions or requests, and our expert team will assist you.
Immunotherapy works by stimulating or restoring the immune system’s ability to recognize and destroy cancer cells. It includes checkpoint inhibitors, CAR‑T cells, and cancer vaccines that target specific molecular pathways. Chemotherapy, on the other hand, is non‑selective and damages both cancerous and healthy rapidly dividing cells, leading to broader side effects. Because immunotherapy is more precise, patients often experience fewer traditional chemotherapy toxicities, though they may develop immune‑related adverse events that require monitoring.
Checkpoint inhibitors such as pembrolizumab and nivolumab target the PD‑1/PD‑L1 or CTLA‑4 pathways, reactivating T‑cells against tumors. They have become standard of care for advanced melanoma, PD‑L1‑positive non‑small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). Additional indications include head and neck squamous cell carcinoma, urothelial carcinoma, and certain gastrointestinal cancers. Eligibility depends on biomarker expression and overall patient health, which Liv Hospital evaluates through molecular profiling.
Personalization begins with a comprehensive diagnostic workup that includes imaging, molecular profiling, and immunohistochemistry to identify biomarkers like PD‑L1. The tumor board—comprising oncologists, radiologists, pathologists, and supportive care specialists—assesses risk‑benefit, discusses patient goals, and selects the optimal drug, dose, schedule, and administration route. Logistics such as travel, interpreter services, and accommodation are coordinated for international patients. The final plan details dosage, frequency, duration, pre‑medication, and monitoring, ensuring clarity for patients and families.
Understanding the challenges of medical tourism, Liv Hospital’s International Desk coordinates visa assistance, arranges airport pickups, and secures discounted hotel rooms near the oncology ward. Multilingual interpreter services are available both on‑site and via video calls for all appointments. A secure digital platform enables patients to upload pathology reports, imaging, and prior treatment summaries, ensuring seamless continuity of care. A pre‑treatment checklist outlines tasks and deadlines, helping patients complete all requirements before their first infusion.
After each infusion, patients undergo baseline blood work to monitor organ function and immune markers. Imaging studies, typically CT or PET scans, are performed every 8–12 weeks to assess tumor response. Telemedicine symptom check‑ins complement in‑person visits, enabling early detection of irAEs. If disease progression or intolerable toxicity occurs, the multidisciplinary team may adjust the dosing schedule, switch agents, or add supportive medications. This dynamic monitoring ensures optimal efficacy while maintaining patient safety throughout the treatment course.
Your Comparison List (you must select at least 2 packages)
